The pharmaceutical sector enters 2026 facing a structural shift in how value is created and defended. A wave of patent expiries is beginning to erode revenues from established blockbusters, while a new generation of therapies prepares to compete in increasingly specialised and technically complex markets. Against this backdrop, scientific innovation remains essential but is no longer sufficient on its own. The ability to communicate that innovation clearly and convincingly to healthcare professionals is becoming a decisive commercial variable.
As legacy products approach the end of their exclusivity periods, companies are balancing short term revenue protection with the demands of launching and scaling new assets. Many of the therapies expected to drive growth in the coming decade are targeted, data rich and supported by intricate clinical narratives. These characteristics may enhance clinical value, but they also raise the bar for effective communication. Prescribers must interpret mechanisms of action, biomarker strategies and comparative evidence in a limited time frame. If messaging fails to land with clarity, adoption curves can flatten and launch investments may underperform expectations.
Artificial intelligence has been widely adopted across research and operational functions, yet its commercial application remains uneven. In 2026, the focus is shifting from experimentation to practical deployment. Tools that measure how scientific messages are understood, retained and differentiated in real world settings are increasingly viewed as essential. Rather than relying on assumptions about message recall or brand awareness, companies are seeking evidence of genuine comprehension and resonance.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
